by myTomorrows | 21 Nov 2019
myTomorrows Collaborates with Precision-Panc UK
myTomorrows Collaborates with Precision-Panc UK, a Member of the International Cancer Genome Consortium, to Help Pancreatic Cancer Patients and Their Physicians
AMSTERDAM, The Netherlands and GLASGOW, United Kingdom, 21 November 2019 – myTomorrows, a global health technology company, is proud to announce a collaboration with Precision-Panc, the largest pancreatic cancer clinical study group of its type in the world. Through this collaboration, myTomorrows and Precision-Panc are working together to create awareness and facilitate access to emerging therapies for patients with pancreatic cancer. The announcement comes during Pancreatic Cancer Awareness Month, as November is dedicated to raising awareness, supporting research and honouring those who fight this disease.
Guided by a patient-first approach, myTomorrows offers a single point of contact for patients with a range of diseases such as cancer, blood disorders and rare diseases. As an innovative health technology company, myTomorrows uses artificial intelligence to search for emerging therapies worldwide. Patients or their treating physicians can fill out a contact form on the myTomorrows website www.mytomorrows.com and then speak directly with a patient navigator who is part of myTomorrows’ medical team. The patient navigator then provides a personalised treatment search report listing possible options — including clinical trials or Expanded Access Programmes (EAPs) — that patients can discuss with their doctors. This service is free of charge for patients and their doctors.
“It is a great honour to announce this collaboration on World Pancreatic Cancer Day. We look forward to this opportunity to help more pancreatic cancer patients and their families,” said Steve Glass, COO of myTomorrows. “myTomorrows and Precision-Panc share a commitment to using technology to enable further understanding of potential treatment options as well as help patients access emerging therapies.”
Under the agreement, patients who contact Precision-Panc but are unsuitable for any of the currently available trials will be able to use myTomorrows’ services to seek other trials or Expanded Access Programmes. If pancreatic patients or their doctors contact myTomorrows they will be informed about other available clinical trials, including Precision-Panc trials or Expanded Access Programmes.
myTomorrows is also working closely with Precision-Panc’s affiliates, including the International Cancer Genome Consortium (ICGC), which leads worldwide efforts to map the genomes of both common and rare cancers in order to accelerate the discovery of new treatments.
Precision-Panc, which was founded in 2017 at the University of Glasgow to help bring precision medicine clinical trials to pancreatic cancer patients, has helped establish a network of over 25 hospitals across the UK that offer these trials. In precision medicine, the DNA of each patient’s cancer is analysed with the aim of matching the right treatment to the right patient. Over time, this will allow doctors to better personalise a person’s treatment, avoiding often toxic treatments when they will not work, and saving time by providing treatments that are more likely to work, explains Professor Andrew Biankin, the Chair and principal investigator of Precision-Panc.
“At the end of the day, we want our patients to access treatments that are most likely to work for them,” said Professor Biankin. “Our collaboration with myTomorrows will help us reach more pancreatic cancer patients and match them with treatments, either through current clinical trials, or through expanded access programmes in the future.”
In addition to November 21st being World Pancreatic Cancer Day, November is also Pancreatic Cancer Awareness Month. Pancreatic cancer is a very complex cancer with few effective treatments. The five-year survival rate for pancreatic cancer patients is only 9 percent. With 10,000 patients diagnosed annually in the UK (330,000 worldwide) and 9,300 deaths a year, pancreatic cancer is predicted to be the second most lethal cancer after lung cancer by 2025.
This collaboration between myTomorrows and Precision-Panc is currently focused on helping patients in the UK and will expand to other European countries in 2020.
About Expanded Access Programmes
An Expanded Access Programme (EAP), also known as a Managed Access Programme, supports in a compliant and controlled way, treatment with a medicine currently not licensed for that indication in a patient’s country of residence. Such treatment can be an option for patients who have a high unmet medical need, have exhausted all registered treatment options and are not eligible to participate in a clinical trial.
myTomorrows operates as a two-sided platform. It serves the interests of both patients and Healthcare Professionals, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialised in Expanded Access Programme regulations and administration and real-world data collection, evolving scientific clinical development. myTomorrows has gained experience in running over 25 EAPs over the past 5 years, in more than 40 countries worldwide. For more information, please visit www.mytomorrows.com
For enquiries about myTomorrows or Expanded Access Programmes, please contact:
Dennis Akkaya, Corporate Development
T: +1 917 373 3862
You may also contact our medical team via firstname.lastname@example.org
In 2017, the Precision-Panc Platform was founded, bringing together expertise in pancreatic cancer from the University of Glasgow, CRUK Beatson Institute, CRUK Cambridge Institute, CRUK Manchester Institute, the Institute of Cancer Research, London, the University of Oxford and the NHS. There is now a UK-wide network of over 20 hospitals that can offer precision medicine clinical trials to patients with pancreatic cancer. For more information about Precision-Panc, visit www.precisionpanc.org
About the ICGC’s ARGO (Accelerating Research in Genomic Oncology) initiative
ICGC-ARGO is an international network of cancer clinicians, researchers and clinical trials groups that aims to address the key questions of:
1. How do we use current treatments better?
2. How does a cancer change with time and treatment?
3. How do we practically implement these approaches in healthcare and therapeutic development?
4. How do we advance early detection and ultimately prevent cancer?